

Amendments to the Claims

1. -16. (Cancelled)

17. (Currently Amended) A method for inducing apoptosis in imatinib mesylate refractory leukemia cells, the method comprising the steps of contacting the living cells with a compound comprising imatinib mesylate and suberoylanilide hydromaxic acid. ~~for about 48 hours;~~

~~wherein the compound has a concentration between about 1.0 μ M and about 10.0 μ M of imatinib mesylate and suberoylanilide hydromaxic acid.~~

18. (Currently Amended) A chemical composition for inducing apoptosis in cancer cells comprising a tyrosine kinase inhibitor and between about 1.0 μ M and about 10.0 μ M ~~of imatinib mesylate and suberoylanilide hydromaxic acid.~~

19. (Previously Presented) A method for inducing apoptosis in cancer cells, the method comprising the steps of contacting the living cells with a tyrosine kinase inhibitor and a histone deacetylase inhibitor.

20. (Previously Presented) The method of claim 19 wherein the tyrosine kinase inhibitor is imatinib mesylate.

21. (Previously Presented) The method of claim 19 wherein the histone deacetylase inhibitor is suberoylanilide hydromaxic acid.

22. (Previously Presented) The method of claim 19 wherein the tyrosine kinase inhibitor is imatinib mesylate and the histone deacetylase inhibitor is suberoylanilide hydromaxic acid.

23. (Previously Presented) Method of claim 19 wherein the living cells are exposed to the tyrosine kinase inhibitor and the histone deacetylase inhibitor for about 48 hours.

24. (Previously Presented) Method of claim 19 wherein the cancer cells are leukemia cells.

25. (Previously Presented) Method of claim 19 wherein the cancer cells are imatinib mesylate refractory.